Societe de Promotion Pharmaceutique du Maghreb Past Earnings Performance
Past criteria checks 2/6
Societe de Promotion Pharmaceutique du Maghreb has been growing earnings at an average annual rate of 11.2%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 10.3% per year. Societe de Promotion Pharmaceutique du Maghreb's return on equity is 14.5%, and it has net margins of 8.8%.
Key information
11.2%
Earnings growth rate
11.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 10.3% |
| Return on equity | 14.5% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Societe de Promotion Pharmaceutique du Maghreb makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 748 | 66 | 234 | 0 |
| 31 Mar 23 | 726 | 70 | 222 | 0 |
| 31 Dec 22 | 705 | 75 | 210 | 0 |
| 30 Sep 22 | 688 | 74 | 203 | 0 |
| 30 Jun 22 | 671 | 72 | 197 | 0 |
| 31 Mar 22 | 651 | 71 | 197 | 0 |
| 31 Dec 21 | 630 | 69 | 198 | 0 |
| 30 Sep 21 | 623 | 71 | 196 | 0 |
| 30 Jun 21 | 616 | 73 | 193 | 0 |
| 31 Mar 21 | 595 | 66 | 184 | 0 |
| 31 Dec 20 | 573 | 60 | 175 | 0 |
| 30 Sep 20 | 556 | 55 | 167 | 0 |
| 30 Jun 20 | 539 | 49 | 159 | 0 |
| 31 Mar 20 | 531 | 51 | 157 | 0 |
| 31 Dec 19 | 522 | 52 | 155 | 0 |
| 30 Sep 19 | 504 | 52 | 156 | 0 |
| 30 Jun 19 | 485 | 52 | 157 | 0 |
| 31 Mar 19 | 465 | 46 | 156 | 0 |
| 31 Dec 18 | 445 | 39 | 154 | 0 |
| 30 Sep 18 | 459 | 44 | 147 | 0 |
| 30 Jun 18 | 474 | 49 | 144 | 0 |
| 31 Mar 18 | 493 | 58 | 144 | 0 |
| 31 Dec 17 | 511 | 66 | 140 | 0 |
| 30 Sep 17 | 516 | 72 | 146 | 0 |
| 30 Jun 17 | 521 | 79 | 152 | 0 |
| 31 Mar 17 | 525 | 83 | 152 | 0 |
| 31 Dec 16 | 530 | 87 | 152 | 0 |
| 30 Sep 16 | 518 | 84 | 152 | 0 |
| 30 Jun 16 | 506 | 81 | 152 | 0 |
| 31 Mar 16 | 519 | 89 | 157 | 0 |
| 31 Dec 15 | 533 | 97 | 161 | 0 |
| 30 Sep 15 | 514 | 92 | 158 | 0 |
| 30 Jun 15 | 494 | 88 | 154 | 0 |
| 31 Mar 15 | 485 | 83 | 149 | 0 |
| 31 Dec 14 | 475 | 78 | 143 | 0 |
| 30 Sep 14 | 472 | 61 | 140 | 0 |
| 30 Jun 14 | 469 | 45 | 137 | 0 |
| 31 Mar 14 | 459 | 48 | 134 | 0 |
| 31 Dec 13 | 449 | 51 | 130 | 0 |
| 30 Sep 13 | 445 | 63 | 134 | 0 |
| 30 Jun 13 | 442 | 75 | 137 | 0 |
Quality Earnings: PRO has high quality earnings.
Growing Profit Margin: PRO's current net profit margins (8.8%) are lower than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRO's earnings have grown by 11.2% per year over the past 5 years.
Accelerating Growth: PRO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PRO had negative earnings growth (-9.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.4%).
Return on Equity
High ROE: PRO's Return on Equity (14.5%) is considered low.